Medical management of peripheral arterial disease

被引:34
作者
Bendermacher, BLW
Willigendael, EM
Teijink, JAW
Prins, MH
机构
[1] Univ Maastricht, KEMTA, Dept Epidemiol, NL-6229 HX Maastricht, Netherlands
[2] Maasland Hosp, Dept Surg, Sittard, Netherlands
[3] Atrium Med Ctr, Dept Surg, Div Vasc Surg, Heerlen, Netherlands
关键词
antiplatelet; atherosclerosis; claudication; critical limb ischemia; management; secondary prevention;
D O I
10.1111/j.1538-7836.2005.01368.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Whether symptomatic or not, peripheral arterial disease (PAD), atherosclerosis in the arteries of the lower extremities, is a common disorder in the general population. The prevalence increases with age and under the influence of vascular risk factors. The most classic symptomatic expression of PAD is intermittent claudication. However, the majority of patients with PAD is asymptomatic or has leg symptoms other than classic intermittent claudication. Both symptomatic and asymptomatic subjects with PAD have increased mortality rates, mainly due to cardiovascular and cerebrovascular expressions of atherosclerotic disease. This review focuses oil the current available medical therapies for PAD, including risk-factor modification and antiplatelet therapies, as well as strategies for symptomatic relief in both patients with intermittent claudication and patients with critical limb ischemia. In general, risk factor modification and antiplatelet therapy is essential in all patients with PAD to prevent systemic atherosclerotic complications. Furthermore. for symptomatic relief exercise therapy is the main intervention while pharmacological treatment should be only complementary. In patients with critical limb ischemia, when revascularization therapy is not possible, an attempt should be made to avoid amputation with conservative treatment using analgesics, vasodilators and/ or anticoagulants. In case of an acute onset of critical limb ischemia, thrombolysis is indicated.
引用
收藏
页码:1628 / 1637
页数:10
相关论文
共 139 条
[1]  
ABBOT NC, 2000, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858.CD001008
[2]   UKPDS 59: Hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes [J].
Adler, AI ;
Stevens, RJ ;
Neil, A ;
Stratton, IM ;
Boulton, AJM ;
Holman, RR .
DIABETES CARE, 2002, 25 (05) :894-899
[3]  
[Anonymous], 1997, ARCH INTERN MED, V157, P2413, DOI DOI 10.1001/ARCHINTE.1997.00440420033005
[4]  
[Anonymous], 1994, BMJ, V308, P81, DOI [10.1136/bmj.308.6921.81, DOI 10.1136/BMJ.308.6921.81]
[5]  
[Anonymous], 2002, COCHRANE DB SYST REV
[6]  
[Anonymous], 2004, Cochrane Database Syst Rev, DOI [DOI 10.1002/14651858.CD000546.PUB2, 10.1002/14651858.CD000546.pub2]
[7]   Natural history of claudication: Long-term serial follow-up study of 1244 claudicants [J].
Aquino, R ;
Johnnides, C ;
Makaroun, M ;
Whittle, JC ;
Muluk, VS ;
Kelley, ME ;
Muluk, SC .
JOURNAL OF VASCULAR SURGERY, 2001, 34 (06) :962-968
[8]   Effect of Simvastatin versus placebo on treadmill exercise time until the onset of intermittent claudication in older patients with peripheral arterial disease at six months and at one year after treatment [J].
Aronow, WS ;
Nayak, D ;
Woodworth, S ;
Ahn, C .
AMERICAN JOURNAL OF CARDIOLOGY, 2003, 92 (06) :711-712
[9]  
Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71
[10]   Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia [J].
Baumgartner, I ;
Pieczek, A ;
Manor, O ;
Blair, R ;
Kearney, M ;
Walsh, K ;
Isner, JM .
CIRCULATION, 1998, 97 (12) :1114-1123